Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522910 | 1.00 | MAPT (0.57) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL31045928 | 0.90 | RAB9A (0.65) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL69866 | 0.90 | RAB9A (0.65) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL69865 | 0.90 | RAB9A (0.65) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL5486185 | 0.86 | TRPA1 (0.67) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL14437429 | 0.86 | TRPA1 (0.67) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| Benzoic Acid SCHEMBL3860616 | 0.83 | TRPA1 (0.69) | MAPTRAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL23554009 | 0.82 | RAB9A (0.55) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL28545671 | 0.82 | KMT2A (0.51) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL21887187 | 0.81 | CA12 (0.68) | MAPTRAB9ANPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466894-B2 | Anti-MUC16 antibodies and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-11 | — | — | US | claimed |
| CN-111579772-B | Detection reagent based on immunomagnetic bead method, preparation method thereof, kit and detection method | 珠海丽珠试剂股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-111579772-A | Detection reagent based on immunomagnetic bead method, preparation method thereof, kit and detection method | 珠海丽珠试剂股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-1920065-B1 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | BIOGEN MA INC (US) | 2018-08-29 | — | — | EP | claimed |
| EP-2087008-A1 | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6 | The Regents of the University of California (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1920065-A4 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | BIOGEN IDEC INC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-2046374-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF SMAD4-DEFICIENT CANCERS | Biogen Idec MA, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008147434-A9 | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN αVβ6 | UNIV CALIFORNIA (US) | 2009-03-05 | — | — | WO | claimed |
| US-20080317667-A1 | Compositions and methods for inhibiting growth of smad4-deficient cancers | BIOGEN IDEC MA INC. (US) | 2008-12-25 | — | — | US | claimed |
| WO-2008147434-A1 | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN αVβ6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-04 | — | — | WO | claimed |
| EP-1920065-A2 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | Biogen Idec MA Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2008008315-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF SMAD4-DEFICIENT CANCERS | BIOGEN IDEC MA INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2007008712-A2 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | BIOGEN IDEC MA INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-05-19 | — | — | US | disclosed |
| US-12617866-B2 | Humanized antibodies to mucin-16 and methods of use thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612456-B2 | CD19 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| EP-1920065-A2 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | Biogen Idec MA Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008008315-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF SMAD4-DEFICIENT CANCERS | BIOGEN IDEC MA INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007008712-A2 | ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF | BIOGEN IDEC MA INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2001094910-A2 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE ANALYSIS OF COMPLEX MIXTURES OF CHEMICAL COMPOUNDS, USING MALDI-TOF MASS SPECTROMETRY | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | CD274, PDCD1LG2, CD2 | MAPT 1326/4885RAB9A 2781/4885NPC1 4727/4885 |
| US-12617866-B2 | Humanized antibodies to mucin-16 and methods of use thereof | MUC1, IGLV6-57, IGSF11 | MAPT 4535/4885RAB9A 4385/4885NPC1 4131/4885 |
| US-12612456-B2 | CD19 antibodies and methods of using the same | CD74, CD4, CD2 | MAPT 4220/4885RAB9A 2744/4885NPC1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.